24 2010
Norwegian Omega-3 oil from Calamari hits the market
Pharma Marine Group, founded by Omega-3 industry veteran Leif Gjendemsjø, has recently introduced Calamarine™ a line of eco-friendly high DHA Omega-3 ingredients for use in dietary supplements, pharmaceuticals and functional food items. Derived from the byproducts of food-grade calamari (Cephalopoda), Calamarine™ Omega-3 oils offer a highly sustainable and environmentally friendly alternative.
Calamari naturally contains high levels of docosahexaenoic acid (DHA). An increasing body of research supports DHA as the more efficacious option for addressing most of the common health conditions supported by Omega-3 supplementation.
15 2009
Roe of fish is best natural source of omega-3
The roe of hake, lumpsucker and salmon is the best dietary source of Omega 3, according to a study carried out by researchers at the University of Almería (UAL). The scientists analysed the eggs, or roe, of 15 marine animals, and found all of these contained high levels of these fatty acids, which are essential to the human body.
Until now there had been no precise understanding of the nutritional potential of the roe of marine animals, but a team of researchers from the UAL has now shown that this is one of the best natural sources of Omega 3 fatty acids, which are essential for ensuring the correct development of a wide variety of metabolic functions in the human body.
The results, published in the European Journal of Lipid Science and Technology, show that Omega 3 fatty acids are present in all fish roe, but especially in the eggs of Atlantic bonito (Sarda sarda), mackerel (Scomber scombrus), squid (Loligo vulgaris), cuttlefish (Sepia sp.), lumpsucker (Cyclopterus lumpus), hake (Merluccius merluccius) and salmon (Salmo salar).
15 2009
Omega-3 entered into Phase 3 clinical programs in Japan
Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and Pronova BioPharma ASA (OSE: PRON.OL) (Lysaker, Norway, “Pronova”) today announced that the advancement of TAK-085 (Compendial name: omega-3 acid ethyl esters 90 (Ph. Eur.)) for the treatment of hypertriglyceridemia into phase 3 clinical programs in Japan.
Takeda and Pronova entered into a license and supply agreement and Pronova granted Takeda an exclusive development, marketing and distribution right in Japan. TAK-085 is a highly concentrated preparation of the ethyl esters of omega-3 fatty acids which are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
TAK-085 has already been approved and is commercially available in the U.S. (marketed as LovazaTM), for the treatment of the adult patients with high triglyceride levels -and major European countries including Italy, France, Germany, Spain and U.K., for the treatment of adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ACE inhibitors) and adult patients with high triglyceride levels.
04 2009
Omega-3 awareness gets its own day in March
Scientific evidence of the health benefits of omega-3’s are now so firmly established that omega-3 expert Carol A. Locke, MD, with a team of world-renowned doctors, has spearheaded the first ever International Omega-3 Awareness Day on March 3rd, 2010
The Omega-3 Day team invites people all over the world both within the healthcare profession and in the public to join in this international effort to save and change lives.
02 2009
Aker BioMarine to be exclusive supplier of company’s Superba™ Krill Oil to Schiff Nutrition International
The biotechnology company Aker BioMarine has signed an agreement to be the exclusive supplier of the company’s Superba™ Krill Oil dietary supplement to the market leader Schiff Nutrition International. The agreement is a major breakthrough for Aker BioMarine in the US market.
01 2009
Omega-3 Fatty Acid Deficiency takes 96,000 Lives Annually in the US
A new study from researchers at the Harvard School of Public Health found Omega-3 deficient diets cause up to 96,000 preventable deaths annually in the United States (US).
“The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors” study published in the April 2009 issue of PLoS Medicine estimated the number of deaths resulting from 12 different modifiable and preventable causes to determine how many deaths were attributable to these factors.
30 2009
Superba Krill Oil found to be better than fish oil
The nutraceutical Superba Krill Oil, rich in omega-3 phospholipids, gives substantially more reduction of fat in the heart and the liver than omega-3 from fish oil. This is demonstrated in a new preclinical study performed for the biotechnological company Aker BioMarine.
The study has been performed by internationally acknowledged research groups in Italy. Under supervision by dr. Sebastiano Banni and dr. Vincenzo Di Marzo, the effect of Superba Krill Oil and omega-3 fish oil was investigated in obese zucker rats.
26 2009
Major NIH Omega-3/Vitamin D Study Begins Jan ‘10
The VITamin D and OmegA-3 TriaL (VITAL) is a research study in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (about 2000 IU) or fish oil (about 1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. Recruitment for the study will begin in January 2010.
23 2009
Omega-3 fatty acids appear to impact AMD progression
Omega-3 fatty acids found in fatty fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD), but the benefits appear to depend on the stage of disease and whether certain supplements are taken, report researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.
11 2008
Capacity Doubled For Marine-Derived Pharmaceutical
Danish firm Pronova BioPharma announced recently that it is to double manufacturing capacity for its marine-derived active pharmaceutical ingredient (API), following increased demand for its omega-3 based drug. Work on the new facility is due to begin, with the plant expected to be operational and approved by regulators by the first half of 2010. The company is investing NOK1.45-1.7bn (€189-222m) on the brand new plant in Kalundborg, Denmark, which will contribute an additional 1,200 tonnes of active ingredient per year and will be fitted out with the same technology and will have the same structure as Pronova’s existing site in Sandefjord. Both production facilities are used to manufacture the API for the company’s Omacor product (Lovaza in the US), which is the first and only EU and US Food and Drug Administration (FDA) approved omega-3 derived prescription drug according to the company, and is prescribed to treat elevated levels of triglycerides, a condition known as hypertriglyceridemia (HTG). Also, the drug has been approved in Europe for patients having just suffered a heart attack.
RSS Feed 
Search
News Archive
Categories
Sponsors
Latest News
- Norwegian Omega-3 oil from Calamari hits the market
- Marine ingredient-based liquid fertilizers promoted for helping plants fight drought in Philippines
- Clay-algal extract combination has use in antibiotec-free animal feed and purification of water from waste effluents
- Marine Ingredient Entrepreneur Talking Up Seaweed and Nova Scotia at the Olympics
- International Seaweed Symposium to be held in Ensenada Baja California México, February 22-26, 2010
Recent Comments
- Kristina on Bodega Algae and Bigelow Lab land SBIR grant
- Research shows effectiveness of natural seaweed extract on … | Health News on Research shows effectiveness of natural seaweed extract on Osteoarthritis symptoms
- Aquapreneur - Research shows effectiveness of natural seaweed … | Health News on Research shows effectiveness of natural seaweed extract on Osteoarthritis symptoms
- Dr Mark G J Hartl on National Seminar on Marine Biotechnology- SEMBIOT ‘10, India
- Ольга on UK’s marine science sector flourishing
Share Aquapreneur
